Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials

Blood. 2019 Mar 7;133(10):1020-1030. doi: 10.1182/blood-2018-06-857102. Epub 2018 Nov 7.


The heterogeneity of myelodysplastic syndromes (MDSs) has made evaluating patient response to treatment challenging. In 2006, the International Working Group (IWG) proposed a revision to previously published standardized response criteria (IWG 2000) for uniformly evaluating clinical responses in MDSs. These IWG 2006 criteria have been used prospectively in many clinical trials in MDSs, but proved challenging in several of them, especially for the evaluation of erythroid response. In this report, we provide rationale for modifications (IWG 2018) of these recommendations, mainly for "hematological improvement" criteria used for lower-risk MDSs, based on recent practical and reported experience in clinical trials. Most suggestions relate to erythroid response assessment, which are refined in an overall more stringent manner. Two major proposed changes are the differentiation between "procedures" and "criteria" for hematologic improvement-erythroid assessment and a new categorization of transfusion-burden subgroups.

MeSH terms

  • Blood Transfusion
  • Cell Lineage
  • Clinical Trials as Topic / standards*
  • Disease Progression
  • Erythrocyte Transfusion
  • Erythrocytes / cytology
  • Hematology / methods*
  • Hematology / standards*
  • Humans
  • International Cooperation
  • Leukocyte Count
  • Myelodysplastic Syndromes / therapy*
  • Neutrophils
  • Platelet Count
  • Practice Guidelines as Topic
  • Quality of Life
  • Recurrence
  • Risk Reduction Behavior
  • Societies, Medical
  • Treatment Outcome